Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Mibavademab by Regeneron Pharmaceuticals for Acquired Generalized Lipodystrophy (Lawrence Syndrome): Likelihood of Approval

Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acquired Generalized Lipodystrophy (Lawrence Syndrome). According...

Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome)

Data Insights

Mibavademab by Regeneron Pharmaceuticals for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome): Likelihood of Approval

Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome). According...

Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome)

Data Insights

Mibavademab by Regeneron Pharmaceuticals for Acquired Generalized Lipodystrophy (Lawrence Syndrome): Likelihood of Approval

Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Acquired Generalized Lipodystrophy (Lawrence Syndrome). According...

Data Insights

Mibavademab by Regeneron Pharmaceuticals for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome): Likelihood of Approval

Mibavademab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome). According...

Sections

Sections

Sections

Sections

Sections

Company Profiles

Mibavademab by Regeneron Pharmaceuticals for Acquired Generalized Lipodystrophy (Lawrence Syndrome): Likelihood of Approval

Mibavademab by Regeneron Pharmaceuticals for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome): Likelihood of Approval

Mibavademab by Regeneron Pharmaceuticals for Acquired Generalized Lipodystrophy (Lawrence Syndrome): Likelihood of Approval

Mibavademab by Regeneron Pharmaceuticals for Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome): Likelihood of Approval